#	Pagina
attuale pagina	/open-h2020/projects/211448/index.html

Opendata, web and dolomites

Fertissimo SIGNED

A ground-breaking medical system selecting the most viable embryo for successful IVF pregnancy

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

Fertissimo project word cloud

Explore the words cloud of the Fertissimo project. It provides you a very rough idea of what is the project "Fertissimo" about.

excellence rates morphology rate centres profile line chances equates accurate pregnancies soon utilises predict validation minimise risk efficient prospective 2009 valencia os standard ivi global fertissimo aran unprecedented diagnostics mass physician lay dependable gold qualify facilities located transfer qualified medical met finances clinical forming oxidative pregnancy company solid reproductive certify engineering practiced multiple clinics quantitative mothers media benefit procedure innovation qualities culture accommodate hospitals tools conduct retrospective embryos rapid stress foundation leader basis viability joins industrially carmel infrastructure create embryo unable incubated single 25 trial series manner forces legacy conclusive invasive low costly ivf outcomes riskier ultimate biomarker

Project "Fertissimo" data sheet

The following table provides information about the project.

Coordinator	CARMEL DIAGNOSTICS LTD Organization address address: 9 BARLEV HAIM STREET city: QIRYAT TIVON postcode: 3608267 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Israel [IL]
Project website	http://www.fertissimoivf.com
Total cost	2˙751˙973 €
EC max contribution	2˙711˙973 € (99%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-2-2016-2017
Funding Scheme	SME-2
Starting year	2017
Duration (year-month-day)	from 2017-05-01 to 2020-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CARMEL DIAGNOSTICS LTD CARMEL DIAGNOSTICS LTD Organization address address: 9 BARLEV HAIM STREET city: QIRYAT TIVON postcode: 3608267 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (QIRYAT TIVON)	coordinator	1˙446˙486.00
2	ARAN RESEARCH DEVELOPMENT & PROTOTYPES LTD ARAN RESEARCH DEVELOPMENT & PROTOTYPES LTD Organization address address: 43 HAESHEL ST city: CAESAEA postcode: 38900 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (CAESAEA)	participant	1˙265˙487.00

Map

Project objective

Low rates of pregnancy in IVF procedure is due to being unable to identify viable embryos for transfer. As a result, multiple embryo transfer (MET) is practiced to increase the chances of pregnancy. This is a costly procedure with riskier outcomes, which on average only equates to a 1 out of 4 rate of pregnancy success. In order to minimise the cost and risk outcomes with MET, there are increasing trends have been adopted to accommodate single embryo transfer (SET). SET however, requires more efficient embryo selection tools than current legacy morphology methods.

Fertissimo utilises a novel biomarker of oxidative stress (OS) qualities that will enable the physician’s selection of viable embryos in a rapid, non-invasive, and accurate manner. Fertissimo will provide a quantitative assessment of an embryo’s reproductive potential based on the oxidative profile of its incubated culture media. It will increase IVF pregnancy outcomes by an unprecedented 25% and beyond.

The Phase 2 project’s ultimate aim is to lay the foundation for dependable IVF pregnancies of the future. Fertissimo will set the gold standard for IVF procedure in all relevant IVF facilities, located in hospitals, medical centres, centres of IVF excellence, and clinics. Carmel Diagnostics will conduct a series of clinical validation studies, both retrospective and prospective, in order to qualify the novel OS biomarker to effectively predict embryo viability

Carmel Diagnostics (established in 2009) joins forces with Aran R&D, a leading engineering and product development company, forming a solid basis with all necessary knowledge capabilities, infrastructure and finances to support the innovation project. This would allow Carmel, and Aran, to develop, test, certify, and create the production line required for Fertissimo’s mass production.

The industrially produced Fertissimo can then be qualified in a conclusive clinical trial with Global IVF Leader IVI Valencia to the benefit of soon-to-be mothers

Deliverables

List of deliverables.
Original Investor Relations Kit Dossier	Websites, patent fillings, videos etc.	2019-03-20 11:46:21
Project website	Websites, patent fillings, videos etc.	2019-03-20 11:46:21

Take a look to the deliverables list in detail: detailed list of Fertissimo deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FERTISSIMO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FERTISSIMO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

PD_Pal (2019)

Palliative care in Parkinson’s disease

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development